HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Beneficial effect of butyrate, Lactobacillus casei and L-carnitine combination in preference to each in experimental colitis.

AbstractAIM:
To investigate the beneficial effect of the combination of butyrate, Lactobacillus casei, and L-carnitine in a rat colitis model.
METHODS:
Rats were divided into seven groups. Four groups received oral butyrate, L-carnitine, Lactobacillus casei and the combination of three agents for 10 consecutive days. The remaining groups included negative and positive controls and a sham group. Macroscopic, histopathological examinations, and biomarkers such as tumor necrosis factor-alpha (TNF-α) and interlukin-1β (IL-1β), myeloperoxidase (MPO), thiobarbituric acid reactive substances (TBARS), and ferric reduced ability of plasma (FRAP) were determined in the colon.
RESULTS:
The combination therapy exhibited a significant beneficial effect in alleviation of colitis compared to controls. Overall changes in reduction of TNF-α (114.66 ± 18.26 vs 171.78 ± 9.48 pg/mg protein, P < 0.05), IL-1β (24.9 ± 1.07 vs 33.06 ± 2.16 pg/mg protein, P < 0.05), TBARS (0.2 ± 0.03 vs 0.49 ± 0.04 μg/mg protein, P < 0.01), MPO (15.32 ± 0.4 vs 27.24 ± 3.84 U/mg protein, P < 0.05), and elevation of FRAP (23.46 ± 1.2 vs 15.02 ± 2.37 μmol/L, P < 0.05) support the preference of the combination therapy in comparison to controls. Although the monotherapies were also effective in improvement of colitis markers, the combination therapy was much better in improvement of colon oxidative stress markers including FRAP, TBARS, and MPO.
CONCLUSION:
The present combination is a suitable mixture in control of experimental colitis and should be trialed in the clinical setting.
AuthorsMahsa Moeinian, Seyedeh Farnaz Ghasemi-Niri, Shilan Mozaffari, Amir Hossein Abdolghaffari, Maryam Baeeri, Mona Navaea-Nigjeh, Mohammad Abdollahi
JournalWorld journal of gastroenterology (World J Gastroenterol) Vol. 20 Issue 31 Pg. 10876-85 (Aug 21 2014) ISSN: 2219-2840 [Electronic] United States
PMID25152589 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents
  • Antioxidants
  • Biomarkers
  • Gastrointestinal Agents
  • Inflammation Mediators
  • Butyric Acid
  • Trinitrobenzenesulfonic Acid
  • Carnitine
Topics
  • Animals
  • Anti-Inflammatory Agents (pharmacology)
  • Antioxidants (pharmacology)
  • Biomarkers (metabolism)
  • Butyric Acid (pharmacology)
  • Carnitine (pharmacology)
  • Colitis (chemically induced, metabolism, microbiology, pathology, therapy)
  • Colon (drug effects, metabolism, microbiology, pathology)
  • Combined Modality Therapy
  • Disease Models, Animal
  • Gastrointestinal Agents (pharmacology)
  • Inflammation Mediators (metabolism)
  • Lacticaseibacillus casei (physiology)
  • Male
  • Oxidative Stress (drug effects)
  • Probiotics (pharmacology)
  • Rats, Wistar
  • Time Factors
  • Trinitrobenzenesulfonic Acid

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: